Evidence map›Paper›PMID 39950270›Full record

ReviewCurrent pharmaceutical biotechnology2025

Recent Advancements in Breast Cancer Therapies and Biomarkers: Mechanisms and Clinical Significance.

Arbab Husain, Hamda Khan, Jamal E Fatima, Shirjeel Ahmad Siddiqui, Akash Deep Singh, Adil Husain, Shivam Pandey, Ravi Kant, Afreen Khanam, Pratibha Pandey and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pharmaceutical biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Arbab HusainDepartment of Biotechnology & Life Sciences, Faculty of Sciences, Mangalayatan University, Aligarh, 202146, Uttar Pradesh, India.
Hamda KhanDepartment of Biochemistry, Faculty of Medicine, Jawahar Lal Nehru Medical College, Aligarh Muslim University, Aligarh, 202002, India.
Jamal E FatimaSchool of Electronic Science and Engineering, University of Electronic Science and Technology of China, Chengdu, China.
Shirjeel Ahmad SiddiquiDepartment of Agricultural Microbiology, Faculty of Agricultural Sciences, Aligarh Muslim University, Aligarh, 202002, Uttar Pradesh, India.
Akash Deep SinghDepartment of Paramedical Sciences, Mangalayatan University, Aligarh, 202146, Uttar Pradesh, India.
Adil HusainDepartment of Biosciences, Integral University, Lucknow, 226026, Uttar Pradesh, India.
Shivam PandeySchool of Applied and Life Sciences, Uttaranchal University, Dehradun, India.
Ravi KantDepartment of Chemistry, Institute of Applied Science, Mangalayatan University, Aligarh, 202146, Uttar Pradesh, India.
Afreen KhanamDepartment of Biotechnology & Life Sciences, Faculty of Sciences, Mangalayatan University, Aligarh, 202146, Uttar Pradesh, India.
Pratibha PandeyCentre of Research Impact and Outcome, Chitkara University, Rajpura, 140417, Punjab, India.
Fahad KhanCenter for Global Health Research Saveetha Medical College, Saveetha Institute of Medical and Technical Sciences, Chennai, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer remains a critical health concern, requiring continual innovation in treatment to improve patient outcomes. The continuous obstacles in therapy and the need for novel techniques underline the importance of making advances in this discipline. Precision medicine has emerged as a viable method, with genomic profiling and molecular subtyping allowing for targeted therapy based on distinct breast cancer subtypes. This strategy is supplemented by advances in early detection and screening, with technologies like liquid biopsy promising earlier and more accurate diagnosis. The introduction of immunotherapy has transformed breast cancer treatment by using the body's immune system to combat cancer. Recent discoveries, particularly combination medicines, attempt to circumvent resistance mechanisms and improve treatment success. Furthermore, including lifestyle therapies such as nutrition, exercise, and psychological support has been demonstrated to reduce breast cancer risk and strengthen survivability rates. Survivorship programs serve an important role in comprehensive care by addressing long-term needs and enhancing survivors' quality of life. Investigating innovative therapeutic approaches, such as developing cancer vaccines, epigenetic modulators, and RNA interference (RNAi) therapy, provides new treatment options. Fostering collaboration among healthcare personnel through shared decision-making and tumor committees is essential for the integration of multidisciplinary care, which ensures patientcentered care. Although advancements have been made, there are still numerous obstacles to overcome in the implementation of these future directions. To effectively confront these obstacles, it is imperative to capitalize on opportunities for innovation and collaboration. It is imperative to address ethical, social, and economic factors in the advancement of breast cancer care to ensure that innovations are equitable and accessible. In conclusion, the future of breast cancer management is bright since substantial improvements are on the verge of turning patient treatment into a completely different experience. For these breakthroughs to become a reality, it is necessary to maintain research efforts, advocate for them, and work together. The dedication to innovation and the joint effort to overcome current problems are the two important factors that will determine whether or not breast cancer treatment and surviving will have a better future.

Indexed as

Biomarkers, TumorBreast NeoplasmsAnimalsClinical RelevanceFemaleHumansImmunotherapyPrecision MedicineBiomarkers, Tumorbreast cancer.early detectionimmunotherapymultidisciplinary carePrecision medicinesurvivorship programs

Identifiers

PMID39950270

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.